Innate Pharma (IPHA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Innate Pharma, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Innate Pharma (IPHA) has returned -26.86% so far this year and -28.09% over the past 12 months.

Based on dividend-adjusted daily data since Oct 17, 2019, IPHA's average daily return is +0.04%, while the average monthly return is -0.65%.

Historically, 41% of months were positive and 59% were negative. The best month was Dec 2022 with a return of +73.5%, while the worst month was Sep 2020 at -38.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, IPHA closed higher 46% of trading days. The best single day was Dec 13, 2024 with a return of +94.8%, while the worst single day was Sep 8, 2020 at -26.8%.

Innate Pharma has an annualized alpha of -0.37%, beta of 0.73, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 18, 2019.

• This stock participated in 97.21% of S&P 500 Index downside but only -16.53% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IPHA ranks 17 for risk / return — in the bottom 17% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Innate Pharma (IPHA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Innate Pharma. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Innate Pharma was 85.73%, occurring on Mar 20, 2026. The portfolio has not yet recovered.

The current Innate Pharma drawdown is 84.39%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Innate Pharma over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Innate Pharma is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.